Harvard Apparatus Regenerative Technology 3Q 2026: Revenue $145K, EPS ($0.08) — 10-Q Summary

Harvard Apparatus Regenerative Technology reported 3Q 2026 revenue of $145K, up 18% YoY, and a net loss of $1.46M, down 14%. Growth came from higher shipments to Health Regen, while R&D costs fell 67% due to lower clinical trial expenses. The company expects current cash to fund operations into 1Q 2027 but needs additional capital.

Original reporting
Published Nov 13, 2026, 4:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 4:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Harvard Apparatus Regenerative Technology 3Q 2026: Revenue $145K, EPS ($0.08) — 10-Q Summary — source image
Decision brief

The 30-second read

$HRGNNeutralMed
01

Why it matters

The earnings beat on loss reduction may attract short‑term buying interest, but the small scale limits broader market impact.

02

Market read

Primary earnings disclosure for a micro‑cap; limited but immediate relevance for traders holding or shorting HRGN.

03

What to watch

Potential need for additional capital and reliance on a single clinical site could limit upside.

Relevance 6/10Novelty 7/10Timing: after-hours release

Background

Harvard Apparatus Regenerative Technology filed its Q3 2026 10‑Q, reporting modest revenue growth and a narrowed net loss.

Company-level read

Ticker impact

$HRGNNeutralMedium confidence
Context

Q3 2026 10‑Q shows revenue $145K (+18%) and net loss narrowing to $1.46M, EPS improving to -$0.08.

Expected impact

likely modest upside as the market prices in the loss improvement.

Evidence & confidence

The company is still loss‑making, but the 14% loss reduction and revenue increase are positive signals for a micro‑cap.

Market effects

Limited; reflects modest growth in the regenerative‑medicine niche.

Minimal; company is small and US‑focused.

Low

Counterpoint

Despite narrowing losses, the company remains cash‑negative and may need dilutive financing, which could pressure the stock.

Key entities

  • Harvard Apparatus Regenerative Technology, Inc.

    Micro‑cap biotech reporting Q3 2026 results.

Related articles

$WMTHighAI 8/10

Walmart Has Raised Its Dividend 53 Straight Years. I'd Buy It Before December and Never Sell.

Walmart (WMT) reported better-than-expected sales and profits, raised its full-year forecast, and announced 53 consecutive years of dividend increases. Despite this, its stock fell 2% in early trading. The company's omnichannel model, advertising business, and AI shopping assistant contributed to its growth, while rising diesel prices and slowing same-store sales growth pose challenges. Walmart's dividend is payable to shareholders of record on December 11.

$ROSTMedAI 8/10

Ross Stores draws more bargain hunters, but higher fuel costs and softer holiday forecast weigh on stock

Ross Stores reported Q3 sales of $6.26B, up 12% YoY, with same-store sales up 8%. Net income rose to $606M ($1.91 per share), beating targets. Shares fell 2.92% as higher fuel costs and a softer holiday forecast weighed on investors. The company maintained its holiday sales growth forecast at 4-5%, down from Q3 and last year's 9%. Ross raised its full-year profit outlook to $8.75-$8.84 per share and opened 51 new stores in Q3, totaling 2,377 stores.

$HDMedAI 8/10

Home Depot Just Delivered Great News to Investors

Home Depot (HD) reported its strongest same-store sales growth since Q3 2022, with 2.2% global and U.S. growth. CFO Richard McPhail becomes CEO, while Ted Decker transitions to chairman. Revenue rose 4.9% to $43.4B, and adjusted EPS increased 3% to $3.86. The company updated its full-year guidance, expecting 4.5% sales growth and 2% EPS increase. Management highlighted strength in professional and high-ticket sales.